Canakinumab for the treatment of autoinflammatory very early onset- inflammatory bowel disease

Overview of attention for article published in Frontiers in immunology, September 2022

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (53rd percentile)
Above-average Attention Score compared to outputs of the same age and source (57th percentile)

So far, Altmetric has seen 6 X posts from 6 X users, with an upper bound of 51,665 followers.

@peiferlabunc @ClementYChow @science_SRH @eperlste And because we (and others) did a retrospective analysis of safety and efficacy could be published. Would a RCT be better…probably, but we couldn’t hang around waiting for that. https://t.co/QG6CrH0w3m

Canakinumab for the treatment of autoinflammatory very early onset- inflammatory bowel disease https://t.co/yO6YMiyKRJ

Eliana Shaul: Canakinumab for the treatment of autoinflammatory very early onset- inflammatory bowel disease https://t.co/ohwUV5DQ5A

RT @FrontImmunol: New Research: Canakinumab for the treatment of autoinflammatory very early onset- inflammatory bowel disease: Introductio…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 2 additional X posts.